Analysis indicates that the current medical aesthetic industry is worth $52,405 million for both service and product revenue. Over the next five years a CAGR of 5.5% is expected and the market will hit $69,786 million in 2021. Currently, invasive aesthetic procedures generated revenues of $27,843.5 million in 2015. Scientific analysis indicate that by 2021, invasive aesthetic procedures will grow at a CAGR of 4.3%, to reach $27,843.5 million. Non-invasive procedures generated approximately $16,738 million in 2015 and will grow at a CAGR of 4.5% over the coming five years. They are expected to generate revenues of $16,738.0 million in 2021. Cosmetic surgery products generated $7,824.0 million in 2015 and have the potential to reach $13,934.0 million in 2021.

Nonsurgical treatments lead the way across the globe and are broadly classified into three major categories: injectable products, energy based devices and active cosmetics. Injectable products include neurotoxins such as Botox and dermal fillers such as Restylane and they have the largest market share. These are followed by energy–based devices such as lasers, radio frequency and intense pulsed light (IPL). Cosmeceuticals include skin care, eye care, skin lightening and scar care products.

The North American market accounts for about 45% of the global market. However, the dominance of the U.S. is shifting towards Asia, particularly in the energy– based devices segment. Asia is regarded as the next frontier and the number of physicians and clinics in China and India has been steadily rising, along with medical tourism in the region. In the injectables and devices category, the E.U. occupies the second position behind the U.S. Brazil continues to be a strong market for aesthetics and cosmetic procedures. The Russian market is also experiencing fast growth compared to many E.U. countries and the Russian market is particularly strong for devices and topicals.

Along with the global giants such as Allergan, Galderma and Merz, a lot of smaller players are offering wrinkle relaxing agents and wrinkle fillers. These products have only temporary effects requiring repeated procedures. The market for these products is nearing maturity and they are widely accepted only in the U.S. and E.U., whereas, permanent fillers are widely in demand in Asia. Artefill is considered to be a semi–permanent to permanent filler. It contains a synthetic ingredient known as polymethyl methacrylate (PMMA) mixed with animal collagen. Use of off–the–shelf dermal fillers and fillers containing lidocaine for pain management is becoming a gold standard in the E.U. and U.S. markets.

Aesthetic practitioners have now the choice of new instrumentations such as soft and bendable needles, blunt-tip cannulas and injector pens for minimally invasive procedures. Recent years have seen wide acceptance by consumers for microneedle treatments administered via handheld guns, for restoring skin with vitamins, amino acids and hyaluronic acid. Consumer aesthetic products such as “micro– botox” and “bro–tox” are experiencing a steady growth. Adipose derived stem cells (ADSC) have gained acceptance for rejuvenating face and breasts, and stem cells from green apple, lilac and alpine roses are now being used as ingredients in topical cosmetics.

Another growth market is for body shaping procedures that involves reduction of fat, cellulite, skin laxity and vein removal. An injectable drug ATX-101 (deoxycholic acid), currently in clinical trials is most likely to become a game changer in body contouring segment in the near future. On July 10, 2014, the FDA accepted the filing of New Drug Application (NDA) for this drug by Kythera Biopharmaceuticals. Plug–in at–home devices for treating sun damage, hair removal, skin discoloration, acne, hair growth, skin texture, microdermabrasion and cellulite continue to expand particularly in developed markets. As a new innovation, the aesthetic market is expected to witness the launch of transepidermal drug delivery technologies for facilitating topical treatments.

According to a latest report published by the official journal of the American Society of Plastic Surgeons (ASPS), service revenues for plastic surgeries rise and fall with economic trends. According to analysis, revenues from surgical procedures are reflected by indicators of macroeconomic climate such as stock market averages. When the stock exchange average rises, revenues from cosmetic surgeries also rise. When unemployment rate goes up, revenues from cosmetic surgeries go down. In the U.S. which is the largest market for cosmetic procedures, overall revenues increased 20%, but there was 10% decline in service revenues from surgical procedures such as breast augmentation and facelift.

On the other hand, trends in minimally invasive procedures are seen reflecting microeconomic indicators. Revenues from minimally invasive procedures increase along with home prices, disposable income per capita and real Gross Domestic Product per capita. Thus, in the recent past, there was a 200% increase in service revenues generated by minimally invasive cosmetic procedures such as botulinum toxin and dermal fillers. The market share for service revenues from these procedures increased from 30% in 2000 to about 50% in past two years. Consequently, service revenues from surgical procedures have nearly remained stable. ASPS surgeons earned service revenues $1,061.4 million for breast augmentation surgeries in 2015.